
Sign up to save your podcasts
Or


In an astonishing story of a scientific discovery, Greg Winter tells Jim Al-Khalili how decades of curiosity-driven research led to a revolution in medicine.
Forced to temporarily abandon his work in the lab when a road rage incident left him with a paralysed right arm, Greg Winter spent several months looking at the structure of proteins. Looking at the stunning computer graphics made the pain in his arm go away. It also led him to a Nobel Prize winning idea: to ‘humanise’ mouse antibodies. A visit to an old lady in hospital made Greg determined to put his research to good use. He fought hard to ensure open access to the technology he invented and set up a start up company to encourage the development of therapeutic drugs. It took years to persuade anyone to fund his Nobel Prize winning idea that led to the creation of an entirely new class of drugs, known as monoclonal antibodies. In 2018, the market for these drugs, which include Humira for rheumatoid arthritis and Herceptin for breast cancer, was worth $70 billion.
By BBC World Service4.4
940940 ratings
In an astonishing story of a scientific discovery, Greg Winter tells Jim Al-Khalili how decades of curiosity-driven research led to a revolution in medicine.
Forced to temporarily abandon his work in the lab when a road rage incident left him with a paralysed right arm, Greg Winter spent several months looking at the structure of proteins. Looking at the stunning computer graphics made the pain in his arm go away. It also led him to a Nobel Prize winning idea: to ‘humanise’ mouse antibodies. A visit to an old lady in hospital made Greg determined to put his research to good use. He fought hard to ensure open access to the technology he invented and set up a start up company to encourage the development of therapeutic drugs. It took years to persuade anyone to fund his Nobel Prize winning idea that led to the creation of an entirely new class of drugs, known as monoclonal antibodies. In 2018, the market for these drugs, which include Humira for rheumatoid arthritis and Herceptin for breast cancer, was worth $70 billion.

7,874 Listeners

854 Listeners

1,074 Listeners

5,565 Listeners

1,805 Listeners

1,761 Listeners

1,051 Listeners

2,000 Listeners

603 Listeners

753 Listeners

93 Listeners

406 Listeners

429 Listeners

821 Listeners

767 Listeners

746 Listeners

231 Listeners

362 Listeners

474 Listeners

241 Listeners

3,222 Listeners

787 Listeners

116 Listeners

1,016 Listeners